Dshea

FDA & Pharmavite join speaker roster for the DSHEA Summit

13-Dec-2023 By Stephen Daniells

Dr Cara Welch, Director of FDA’s Office of Dietary Supplements Programs, and Christine Burdick-Bell, EVP & General Counsel at Pharmavite, have confirmed their participation in the NutraIngredients-USA’s landmark DSHEA Summit.

Announcing the DSHEA Summit: A landmark event bringing together the architects of the law & leading industry voices

04-Dec-2023 By Stephen Daniells

Join Scott Bass, Loren Israelsen, Bob Durkin, Jim Emme, and more industry luminaries for NutraIngredients-USA’s landmark DSHEA Summit.

Jim Kababick on 30 years in the industry: ‘Working together to solve our problems is probably the best thing we’ve done to push the industry forward’

28-Sep-2023 By Stephen Daniells

“If people who don’t understand the industry spent a day looking at what goes on behind the curtain, they’d be blown away,” said Jim Kababick, founder of Flora Research Laboratories, as he looked back on 30 years in the industry.

Bipartisan support for cannabidiol puts FDA, CBD coalitions in spotlight

26-Sep-2023 By Claudia Adrien

Advocates say there’s momentum in Congress to offer regulatory guidance for CBD supplement use.

CRN at 50: Our underlying values haven’t changed

18-Sep-2023 By Stephen Daniells

As the Council for Responsible Nutrition celebrates its 50th anniversary, NutraIngredients-USA caught up with Steve Mister, CRN President and CEO, to hear about the association’s history, its commitment to its founding values, and how it is gearing up...

Dietary supplement industry remembers Bill Richardson

12-Sep-2023 By Asia Sherman

Former New Mexico governor and congressman Bill Richardson, who died Sept. 1 at age 75, dedicated his life to public service and freeing political hostages, but he also championed the dietary supplement industry when it needed it most.

CRN urges FDA to put resources behind enforcing supplement master file framework

14-Aug-2023 By Stephen Daniells

The Council for Responsible Nutrition (CRN) has written to the US Food & Drug Administration urging the agency to put resources behind any dietary supplement master file framework, or rethink prioritizing a master files guidance.

CBD stakeholder’s call: “It’s really in Congress’ hands”

01-Jun-2023 By Danielle Masterson

With the ongoing theme of safety, FDA recently addressed CBD. While offering up several potential scenarios, the Agency said the CBD marketplace ultimately rests in the hands of Congress.

SCOTUS to decide case on government power

04-May-2023 By Danielle Masterson

As the justices weigh in on interpretive authority, we explore what this could mean for the dietary supplement industry.

Trades weigh in on call to clean up dietary supplement industry

31-Mar-2023 By Asia Sherman

In a recent letter to Congress, supplement company Ritual urged lawmakers to clean up a dietary supplement industry that has grown twenty-fold since the enactment of the Dietary Supplement Health and Education Act nearly 30 years ago.

Ritual urges Congress to clean up the dietary supplement industry

23-Mar-2023 By Asia Sherman

In a letter addressed to the 118th Congress last week, supplement company Ritual is appealing to lawmakers to address key safety and efficacy issues in a bourgeoning dietary supplement industry.

Top 8 takeaways from Regulatory Summit

26-Jul-2022 By Danielle Masterson

This year’s Dietary Supplement Regulatory Summit in Washington, DC, featured updates and insights from top FDA officials, including the Office of Dietary Supplement Programs along with top stakeholders and industry experts. Here are a few key takeaways...

‘A titan of the Senate’: Supplements industry pays tribute to Sen. Orrin Hatch

25-Apr-2022 By Stephen Daniells

The dietary supplements industry has been paying tribute to the Senator Orrin Hatch, who passed away on Saturday, April 23, 2022 in Salt Lake City, Utah at the age of 88.

FDA proposes mandatory product listing, industry stakeholders divided

29-Mar-2022 By Danielle Masterson

The fiscal year 2023 budget request marks a 34% increase and highlights immediate priorities, including modernizing DSHEA.

Ex-Health Canada NHP DG on product registration: ‘You have to ask yourself why you are doing it’

05-Aug-2021 By Stephen Daniells

As the conversation around modernizing DSHEA hots up in the US and calls for a mandatory product registration intensify, we caught up with the former Director General of Health Canada’s NHP Directorate to hear about his experiences regulating Natural...

FDA’s Welch on DSHEA 2.0: ‘We have an opportunity for real, common sense reform that I don’t believe we can let pass by’

25-May-2021 By Stephen Daniells

“FDA is not looking to throw out DSHEA and start fresh – rather we are talking about building on the current framework,” said FDA’s Dr Cara Welch. Done correctly, initiatives like a mandatory product listing would not impose significant burdens on the...

UNPA's Israelsen on DSHEA 2.0 & CBD: ‘Unless there is unity, it just gets harder’

29-Apr-2021 By Stephen Daniells

Proposed modernizations to the Dietary Supplement Health and Education Act (DSHEA) and solutions to the CBD issue require “an outstanding effort by industry to speak with a united voice”, says Loren Israelsen, President of the United Natural Products...

AHPA's McGuffin on DSHEA 2.0, CBD's path forward, and more

20-Apr-2021 By Stephen Daniells

While AHPA supports H.R.841, the association wishes FDA “would do its job and establish a legal pathway [for hemp and CBD], but they haven’t,” said Michael McGuffin. “Something needs to happen.”

CRN’s Mister on the best solution for CBD, DSHEA 2.0, and more

14-Apr-2021 By Stephen Daniells

The Hemp and Hemp-Derived CBD Consumer Protection and Market Stabilization Act represents ‘the best way’ to deal with the hemp-CBD issue for dietary supplements, says CRN’s Steve Mister, and once that’s clarified then the FDA and industry can address...

NPA’s Fabricant on CBD, NDI-related import alerts, and banned stimulants

01-Apr-2021 By Stephen Daniells

Efforts to move the needle on hemp-CBD at the Federal level are slow, and upcoming exits of key personnel at FDA are unlikely to affect progress much, says NPA’s Dr Daniel Fabricant. “In some ways I think FDA likes the status quo,” he tells NutraIngredients-USA.

Probiota Champions: In conversation with Jarrow Rogovin

Jarrow Rogovin: ‘Dietary supplements are American folk medicine’

18-Nov-2020 By Stephen Daniells

“Dietary supplements are American folk medicine, and it’s a fascinating one because it involves a lot of good science… and – very importantly – we have a regulatory framework, DSHEA, that’s rational,” Jarrow Rogovin told NutraIngredients-USA recently.

FDA’s Tave: Mandatory product listing would be ‘a dramatic step forward in narrowing the regulatory gap’

15-Oct-2020 By Stephen Daniells

“We cannot enforce against what we cannot see or cannot know is there”, said FDA’s Steven Tave, and that’s why mandatory listing requirement for dietary supplement products would be a step forward for enforcement.

FDA’s Tave highlights ‘Regulatory Gap’ for dietary supplements

17-Sep-2020 By Stephen Daniells

A ‘Regulatory Gap’ exists within the US dietary supplements industry, and recent talk of modernizing the regulations are ways to close that gap, FDA’s Steven Tave said yesterday

Guest article

New Dietary Ingredients: Will FDA protect consumers from pirates and piggybackers?

05-Aug-2020 By Steve Mister, President & CEO, Council for Responsible Nutrition

Why is it so hard to get FDA to enforce the law when it comes to NDIs?

NutraCast Podcast: CSPI’s Laura MacCleery on ‘antiviral' supplements in the marketplace

04-Aug-2020 By Danielle Masterson

Over 70% of Americans take dietary supplements, and by now, most consumers have probably noticed the disclaimer that says "This statement has not been evaluated by the FDA. This product is not intended to diagnose, treat, cure, or prevent any disease.”

UNPA’s Israelsen: ‘We’ve had a good six weeks, but consumers have used some of their last spending power to buy supplements’

04-May-2020 By Stephen Daniells

While dietary supplement sales have surged in recent months, the extent of the economic damage caused by the novel coronavirus and COVID-19 could lead to some very tough quarters as families and businesses start to run out of money.

Guest article

The irrationality of probiotic dissension

09-Apr-2020

“The Probiotic Conundrum”, an article published last month in JAMA, has received a lot of criticism from experts in the field. Professor Gregor Reid, PhD, MBA, penned a counterpoint to the article and submitted it to JAMA. The journal rejected his submission....

Probiotics stakeholders fire back at JAMA article calling for drug regulations for bugs

01-Apr-2020 By Stephen Daniells

Industry experts have slammed statements made in a recent JAMA Viewpoint that called for probiotics to be regulated to the same standard as drugs, and decried the “paucity of high-quality data supporting the value of probiotics”.

Industry stakeholders lay out safety, regulatory challenges

23-Mar-2020 By Danielle Masterson

The Natural Products Association (NPA) recently held a webinar on political and legislative insights. At the forefront — the expansion of health savings accounts, new dietary new dietary ingredient enforcement, DSHEA, accurate labels, and Cannabidiol...

CBD paves way for marijuana leniency in NFL

16-Mar-2020 By Danielle Masterson

As legal marijuana expansion continues, advocates point out that it is a safer alternative to prescription opioids for athletes to manage their pain. Thanks to a new agreement, NFL players have that option.

2020 predictions: Staff changes at FDA, CBD, personalization, and the microbiome

15-Jan-2020 By Stephen Daniells

The year is new and a lot of people are getting out their crystal balls. NutraIngredients-USA is no exception, and here are our top big issues that will impact the dietary supplements industry in this new decade.

Guest article

The legacy of 2019: CBD, mandatory listing and discord

19-Dec-2019 By Steve Mister, President & CEO, Council for Responsible Nutrition

The question of CBDs, and of a mandatory product listing, have dominated a year that for the dietary supplement industry has not been as tumultuous as some.

From the editor's desk

While unlikely, new framework for disseminating study results would improve DSHEA

15-Nov-2019 By Hank Schultz

The turmoil surrounding the CBD question has obscured other important debates, such as how to alter DHSEA is such a way that more scientific information can be conveyed to consumers.

NPA’s Fabricant talks DSHEA 2.0, mandatory product listing, user fees, and CBD

13-Nov-2019 By Stephen Daniells

Introducing user fees for the food industry – of which dietary supplements are a subset – is a tough proposition, says Dan Fabricant, president and CEO of the Natural Products Association.

Navajo Nation’s first hemp products store open for business

08-Oct-2019 By Danielle Masterson

In 1988, the Native American economy got a major boost with the legalization of the Indian gaming industry. Thirty years later, a new legalization is offering yet another revenue stream: hemp.

Editor's Spotlight

Nature's Way strategy and innovation chief shares how a legacy company is keeping up with the times

27-Mar-2019 By Adi Menayang

At the Natural Products Expo West show this year, we caught up with the chief strategy and innovation officer at legacy supplement brand Nature’s Way to talk about consumer trends, CBD, and the body of laws that regulate supplements.

Ancient Nutrition founder on new products, DSHEA at 25 and hemp-CBD

15-Mar-2019 By Stephen Daniells

With growth “like a rocket ship”, a new range of hemp-CBD products, and a continued commitment to keto and protein, “2019 is going to be a great year”, says Ancient Nutrition product innovator and founder, Jordan Rubin.